Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials
Journal of Clinical Oncology · 10.04.2026 · 44 (11) · 1028-1039
DOI: 10.1200/jco-25-02111 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2026. Verfasst von Sai-Wei Huang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and…. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Biomarkers, Tumor, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Personalized immunotherapy strategies are urgently needed for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). We aim to identify biomarkers predictive of immunotherapy benefits, using data from the phase III CONTINUUM (ClinicalTrials.gov identifier: NCT03700476 ) and DIPPER (ClinicalTrials.gov identifier: NCT03427827 ) randomized clinical trials. PATIENTS AND METHODS Tumor samples from 407 patients in the CONTINUUM (discovery cohort) and DIPPER (validation cohort) trials were subjected to RNA sequencing. In the discovery cohort, metabolic gene-based consensus clustering was performed to determine subtypes. A machine learning–based classifier was subsequently developed in the discovery cohort and then applied to the validation cohort to assign metabolic subtypes. Gene set enrichment analyses were used to characterize the biological features of each metabolic subtype. The clinical end point was event-free survival (EFS). RESULTS In the discovery cohort, three metabolic subtypes were identified with distinct tumor-intrinsic and immune features as well as differential EFS benefits from adding anti–PD-1 to chemoradiotherapy (CRT). Specifically, the MS1 subtype exhibited a significant improvement in 3-year EFS in the anti–PD-1 plus CRT arm compared with the CRT-alone arm (3-year EFS, 90.2% v 69.6%; hazard ratio, 0.27 [95% CI, 0.11 to 0.67]), whereas MS2 (3-year EFS, 94.1% v 93.8%) and MS3 subtypes (3-year EFS, 75.0% v 75.0%) derived no significant survival benefit. The subtype features were preserved in the validation cohort, with consistent prognostic and predictive value. A pooled analysis of both cohorts demonstrated the significant interaction between metabolic subtypes and the treatment effect ( P interaction = 0.0074). CONCLUSION In this biomarker study, we defined metabolic subtypes of NPC that predicted the EFS benefit from immunotherapy. This novel molecular classification provides a promising predictive biomarker for personalized treatment decision for patients with locoregionally advanced NPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Su…
- Department of Experimental Research, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer,…
- Department of Radiation Oncology, The First People's Hospital of Foshan, Foshan, China.
- Department of Pathology, The First People's Hospital of Foshan, Foshan, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
- Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
ORCID-Profile: Wen-Fei Li, Sha Xu, Xu Liu, Feng Jin, Ling-Long Tang, Ying Sun, Ying-Qin Li, Jun Ma, Na Liu
Zitieren
APA
Huang, S. W., Liang, Y. L., Tao, Y. L., Li, W. F., Zhou, G. Q., Mao, Y. P., Guo, R., Chen, L., Xu, S., Liu, X., Zhang, N., Liu, F., Shen, L. F., Zhou, Y. Y., Yuan, Y. W., Zou, G. R., Jin, F., Tang, L. L., Sun, Y., …, & Liu, N. (2026). Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials. Journal of Clinical Oncology, 44(11), 1028-1039. https://doi.org/10.1200/jco-25-02111
Vancouver
Huang SW, Liang YL, Tao YL, Li WF, Zhou GQ, Mao YP, et al. Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials. Journal of Clinical Oncology. 2026;44(11):1028-1039. doi:10.1200/jco-25-02111
BibTeX
@article{Huang2026,
author = {Huang, Sai-Wei and Liang, Ye-Lin and Tao, Ya-Lan and Li, Wen-Fei and Zhou, Guan-Qun and Mao, Yan-Ping and Guo, Rui and Chen, Lei and Xu, Sha and Liu, Xu and Zhang, Ning and Liu, Fang and Shen, Liang-Fang and Zhou, Yang-Ying and Yuan, Ya-Wei and Zou, Guo-Rong and Jin, Feng and Tang, Ling-Long and Sun, Ying and Li, Ying-Qin and Ma, Jun and Liu, Na},
title = {Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {11},
pages = {1028--1039},
doi = {10.1200/jco-25-02111}
}
EUVIMED